vs
Limoneira CO（LMNR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Limoneira CO的季度营收约是REGENXBIO Inc.的1.4倍（$41.3M vs $30.3M），Limoneira CO净利率更高（-21.0% vs -221.3%，领先200.3%），REGENXBIO Inc.同比增速更快（43.0% vs -2.8%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 3.8%）
Limoneira是总部位于美国加利福尼亚州的领先农业企业，主营柑橘、牛油果等特色农产品的种植、加工与分销，产品销往北美、亚洲、欧洲等市场，服务零售及餐饮客户，同时布局可持续土地开发相关业务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LMNR vs RGNX — 直观对比
营收规模更大
LMNR
是对方的1.4倍
$30.3M
营收增速更快
RGNX
高出45.8%
-2.8%
净利率更高
LMNR
高出200.3%
-221.3%
两年增速更快
RGNX
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.3M | $30.3M |
| 净利润 | $-8.7M | $-67.1M |
| 毛利率 | -15.1% | — |
| 营业利润率 | -26.8% | -190.0% |
| 净利率 | -21.0% | -221.3% |
| 营收同比 | -2.8% | 43.0% |
| 净利润同比 | -367.5% | -31.2% |
| 每股收益（稀释后） | $-0.49 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LMNRRGNX
| Q4 25 | $41.3M | $30.3M | ||
| Q3 25 | $45.9M | $29.7M | ||
| Q2 25 | $33.6M | $21.4M | ||
| Q1 25 | $32.9M | $89.0M | ||
| Q4 24 | $42.5M | $21.2M | ||
| Q3 24 | $61.8M | $24.2M | ||
| Q2 24 | $43.3M | $22.3M | ||
| Q1 24 | $38.3M | $15.6M |
净利润LMNRRGNX
| Q4 25 | $-8.7M | $-67.1M | ||
| Q3 25 | $-855.0K | $-61.9M | ||
| Q2 25 | $-3.4M | $-70.9M | ||
| Q1 25 | $-3.1M | $6.1M | ||
| Q4 24 | $-1.9M | $-51.2M | ||
| Q3 24 | $6.6M | $-59.6M | ||
| Q2 24 | $6.6M | $-53.0M | ||
| Q1 24 | $-3.6M | $-63.3M |
毛利率LMNRRGNX
| Q4 25 | -15.1% | — | ||
| Q3 25 | 8.5% | — | ||
| Q2 25 | 5.6% | — | ||
| Q1 25 | -2.0% | — | ||
| Q4 24 | 6.3% | 70.2% | ||
| Q3 24 | 26.5% | 48.8% | ||
| Q2 24 | 6.5% | 52.5% | ||
| Q1 24 | -2.0% | 72.6% |
营业利润率LMNRRGNX
| Q4 25 | -26.8% | -190.0% | ||
| Q3 25 | -1.4% | -176.3% | ||
| Q2 25 | -10.0% | -296.3% | ||
| Q1 25 | -16.3% | 13.6% | ||
| Q4 24 | -6.5% | -242.1% | ||
| Q3 24 | 14.5% | -256.6% | ||
| Q2 24 | -10.8% | -251.3% | ||
| Q1 24 | -20.2% | -408.8% |
净利率LMNRRGNX
| Q4 25 | -21.0% | -221.3% | ||
| Q3 25 | -1.9% | -208.3% | ||
| Q2 25 | -10.0% | -331.8% | ||
| Q1 25 | -9.4% | 6.8% | ||
| Q4 24 | -4.4% | -241.3% | ||
| Q3 24 | 10.7% | -246.3% | ||
| Q2 24 | 15.2% | -237.7% | ||
| Q1 24 | -9.4% | -405.4% |
每股收益（稀释后）LMNRRGNX
| Q4 25 | $-0.49 | $-1.30 | ||
| Q3 25 | $-0.06 | $-1.20 | ||
| Q2 25 | $-0.20 | $-1.38 | ||
| Q1 25 | $-0.18 | $0.12 | ||
| Q4 24 | $-0.09 | $-0.99 | ||
| Q3 24 | $0.35 | $-1.17 | ||
| Q2 24 | $0.35 | $-1.05 | ||
| Q1 24 | $-0.21 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $72.5M | — |
| 股东权益账面价值 | $180.0M | $102.7M |
| 总资产 | $311.1M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.40× | — |
8季度趋势，按日历期对齐
现金及短期投资LMNRRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务LMNRRGNX
| Q4 25 | $72.5M | — | ||
| Q3 25 | $63.4M | — | ||
| Q2 25 | $55.0M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $40.6M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $60.1M | — | ||
| Q1 24 | $52.1M | — |
股东权益LMNRRGNX
| Q4 25 | $180.0M | $102.7M | ||
| Q3 25 | $180.3M | $161.5M | ||
| Q2 25 | $182.7M | $213.7M | ||
| Q1 25 | $186.5M | $274.2M | ||
| Q4 24 | $191.7M | $259.7M | ||
| Q3 24 | $194.9M | $301.4M | ||
| Q2 24 | $189.0M | $348.3M | ||
| Q1 24 | $184.2M | $390.7M |
总资产LMNRRGNX
| Q4 25 | $311.1M | $453.0M | ||
| Q3 25 | $299.9M | $525.2M | ||
| Q2 25 | $296.6M | $581.0M | ||
| Q1 25 | $301.4M | $490.9M | ||
| Q4 24 | $298.8M | $466.0M | ||
| Q3 24 | $307.3M | $519.1M | ||
| Q2 24 | $322.2M | $569.4M | ||
| Q1 24 | $299.6M | $629.2M |
负债/权益比LMNRRGNX
| Q4 25 | 0.40× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 0.21× | — | ||
| Q2 24 | 0.32× | — | ||
| Q1 24 | 0.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $942.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LMNRRGNX
| Q4 25 | $942.0K | $-52.3M | ||
| Q3 25 | $-3.0M | $-56.0M | ||
| Q2 25 | $8.9M | $-49.3M | ||
| Q1 25 | $-12.9M | $33.6M | ||
| Q4 24 | $6.6M | $-31.6M | ||
| Q3 24 | $24.6M | $-40.5M | ||
| Q2 24 | $-3.0M | $-45.5M | ||
| Q1 24 | $-10.3M | $-55.5M |
自由现金流LMNRRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率LMNRRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度LMNRRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率LMNRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.73× | — | ||
| Q2 24 | -0.46× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LMNR
| Lemon Packing | $33.9M | 82% |
| Other Agribusiness | $5.8M | 14% |
| Fresh Lemons | $1.3M | 3% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
